title: Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6.
authors.affiliation: Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK. gordon.wishart@addenbrookes.nhs.uk
authors.forename: Gordon C
authors.initials: GC
authors.lastname: Wishart
authors.forename: Udi
authors.initials: U
authors.lastname: Chetty
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001940:Breast / Q000187:drug effects / Q000473:pathology / Q000601:surgery; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D004164:Diphosphonates / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D000077289:Letrozole; D008403:Mass Screening; D008408:Mastectomy / Q000379:methods / Q000706:statistics & numerical data*; D009570:Nitriles / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D013629:Tamoxifen / Q000008:administration & dosage; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage; D000077211:Zoledronic Acid
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004164:Diphosphonates; D007093:Imidazoles; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077211:Zoledronic Acid; D000077289:Letrozole